EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Extramedullary Disease—Achilles Heel in Myeloma?

Shaji Kumar iD, Joshua Richter iD, Saad Z Usmani, Yael C Cohen iD, Jing Christine Ye, María-Victoria Mateos, Vania Hungria iD, Elena Zamagni

American Journal of Hematology · 2026-03 · 101 (3) · 521-536

DOI: 10.1002/ajh.70138 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 29.12.2025. Verfasst von Shaji Kumar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Rochester, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Plasmacytoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Johnson & Johnson, Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion molecules, heterogeneous genetic and epigenetic changes, and a solid tumor‐like architecture within the microenvironment. Although the introduction of advanced imaging techniques and immunotherapy has led to improved detection and more promising outcomes and regimens, respectively, more prospective studies dedicated to true EMD are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaPlasmacytomaHumansTumor MicroenvironmentPrognosis

Stichwörter der Autor:innen

bispecific antibodiesimmunotherapyparamedullaryrelapsed myeloma

Autor:innen und Institutionen

  • Mayo Clinic Rochester, Rochester, Minnesota, USA.
  • Mount Sinai School of Medicine, New York, New York, USA.
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel.
  • Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • MD Anderson Cancer Center, University of Texas, Houston, Texas, USA.

ORCID-Profile: Shaji Kumar, Joshua Richter, Yael C Cohen, Vania Hungria

Förderung

  • NCI NIH HHS
  • Johnson & Johnson
  • Janssen Research and Development

Zitieren

APA

Kumar, S., Richter, J., Usmani, S. Z., Cohen, Y. C., Ye, J. C., Mateos, M. V., Hungria, V., & Zamagni, E. (2026). Extramedullary Disease—Achilles Heel in Myeloma?. American Journal of Hematology, 101(3), 521-536. https://doi.org/10.1002/ajh.70138

Vancouver

Kumar S, Richter J, Usmani SZ, Cohen YC, Ye JC, Mateos MV, et al. Extramedullary Disease—Achilles Heel in Myeloma?. American Journal of Hematology. 2026;101(3):521-536. doi:10.1002/ajh.70138

BibTeX
@article{Kumar2026,
  author = {Kumar, Shaji and Richter, Joshua and Usmani, Saad Z and Cohen, Yael C and Ye, Jing Christine and Mateos, María-Victoria and Hungria, Vania and Zamagni, Elena},
  title = {Extramedullary Disease—Achilles Heel in Myeloma?},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {3},
  pages = {521--536},
  doi = {10.1002/ajh.70138}
}
Kostenlos starten →